logo-loader
viewTissue Regenix Group PLC

Tissue Regenix MD says the company is at an "exciting period"

Antony Odell, MD of Tissue Regenix (LON:TRX), explains to Proactiveinvestors that the company is at an "exciting period" in its development and, because it is a medical devices company, it is a "lower risk, lower cost and more predictable" business model than a biotech business. Antony also explains that the real benefits of the TRX patented technology are the opportunities from "big unmet needs" in the aging population.

Quick facts: Tissue Regenix Group PLC

Price: 1.5675 GBX

AIM:TRX
Market: AIM
Market Cap: £18.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

4 weeks, 1 day ago

2 min read